PeptideStack
5.2kquestions
20kanswers
220users

Would you accept 98.8% on tirzepatide from WXT without a content assay?

Asked 18 Jun 2024Modified 22 months agoViewed 23k times
5

Conditions: 98.8% · tirzepatide · WXT.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

What would you do, and what would make you change course?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
BF
askedbea_forsberg14k2818 Jun 2024
4Does this hold at lower concentrations, or does adsorption dominate? – ayo_fadipe 3 months ago
5Worth flagging that this changed in 2025, so older answers on the site are out of date. – nine_point_nine 5 months ago
add a comment

5 Answers

Accepted answer first, then by votes
135

Accepted answer

The part that matters: the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
AF
answered · acceptedayo_fadipe19k2824 Jul 2024
8This should probably be in the site help pages rather than buried in an answer. – b_delacroix 3 months ago
Good answer, but the confidence interval in the cited trial is wider than implied. – amara_nwachukwu 5 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
52

Reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

On the detail: integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 24 Aug 2024 by nine_point_nine — added the placebo-arm figures

shareimprove this answerflag
NN
answerednine_point_nine45k1385 Aug 2024
8The distinction between purity and content cannot be repeated often enough here. – lyoph_cake 5 months ago
add a comment
31

Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
OB
answeredotto_brenner19k2813 Jul 2024
The arithmetic checks out. I ran the same numbers and got the same result. – vialroom 8 months ago
add a comment
25

Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 22 Sept 2024 by fib4_reader — added the method parameters

shareimprove this answerflag
FR
answeredfib4_reader35k387 Sept 2024
-2

Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
ED
answerede_dziedzic87k2482 Jul 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.